Results from study of PQ Birch are expected in the second half of this year. Researchers will assess the efficacy of the aluminium-free inoculation alongside the safety of the injection.
READ: Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic
A total of 560 people from 59 different centres in Germany, Austria, Poland and Sweden are taking part in the trial, which will get underway during birch pollen season.
Success would pave the way for marketing authorisation. Chief executive Manuel Llobet said the successful development of PQ Birch would “strengthen the group's portfolio and help address the current unmet needs”.
The product is one of a number of ultra-short course, injected immunotherapy products in clinical development for various allergies, which are part of Allergy Therapeutics’ three-pillar strategy. The company is investing heavily from its growing revenue stream in its pipeline as well as expanding its base in Europe, while preparing for entry to the US.